1. Home
  2. TTRX vs OTGA Comparison

TTRX vs OTGA Comparison

Compare TTRX & OTGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$9.31

Market Cap

298.8M

Sector

Health Care

ML Signal

N/A

OTGA

OTG Acquisition Corp. I Class A Ordinary Share

N/A

Current Price

$10.29

Market Cap

300.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TTRX
OTGA
Founded
2015
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
298.8M
300.9M
IPO Year
2025
2025

Fundamental Metrics

Financial Performance
Metric
TTRX
OTGA
Price
$9.31
$10.29
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $25.00
N/A
AVG Volume (30 Days)
★ 83.6K
69.1K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$900.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$9.97
52 Week High
$16.45
$10.32

Technical Indicators

Market Signals
Indicator
TTRX
OTGA
Relative Strength Index (RSI) 42.37 59.37
Support Level $8.75 $10.03
Resistance Level $11.17 N/A
Average True Range (ATR) 0.98 0.01
MACD 0.06 0.00
Stochastic Oscillator 39.55 61.54

Price Performance

Historical Comparison
TTRX
OTGA

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About OTGA OTG Acquisition Corp. I Class A Ordinary Share

OTG Acquisition Corp I is a newly organized blank check company.

Share on Social Networks: